NCT01577680View on ClinicalTrials.gov

A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 5, 2012

Primary Completion Date

June 29, 2012

Study Completion Date

June 29, 2012

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Inhaled GSK573719/vilanterol

All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1

DRUG

Inhaled GSK573719

All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2

Trial Locations (2)

H-1115

GSK Investigational Site, Budapest

831 01

GSK Investigational Site, Bratislava

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01577680 - A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers | Biotech Hunter | Biotech Hunter